The landmark litigation attempting to remove mifepristone from the market involves issues central to the US Food and Drug Administration’s regulation of drug products. The outcome will impact who is able to file suit to seek reversal of a drug approval and whether courts can set aside the agency’s evaluation of scientific data.
Below are the arguments the parties made in filings with the US Court of Appeals for the Fifth Circuit. The FDA appealed a district court order suspending the agency’s 2000...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?